利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.016 秒)

    OXIDIZED LIPIDS IN THE TREATMENT OF CHRONIC OR NEUROPATHIC PAIN
    8.
    发明公开
    OXIDIZED LIPIDS IN THE TREATMENT OF CHRONIC OR NEUROPATHIC PAIN 审中-公开
    氧化脂质治疗慢性或神经性疼痛

    公开(公告)号：EP3207926A1

    公开(公告)日：2017-08-23

    申请号：EP16156194.9

    申请日：2016-02-17

    申请人： Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. ,  Goethe-Universität Frankfurt am Main

    发明人： SISSIGNANO, Marco ,  GEISSLINGER, Gerd ,  PARNHAM, Michael John

    IPC分类号： A61K31/201 ,  A61K31/336 ,  A61K31/4184 ,  A61K31/445 ,  A61K31/496 ,  A61P25/02 ,  G01N33/68

    CPC分类号： A61K31/201 ,  A61K31/336 ,  A61K31/4184 ,  A61K31/445 ,  A61K31/496 ,  G01N33/92 ,  G01N2800/2842 ,  G01N2800/50

    摘要： Neuropathic pain is a debilitating disease with poor treatment options. Clinical investigations conclude that early therapeutic intervention is crucial for increasing the therapeutic success and for ameliorating neuropathic pain. However, in patients with diabetes or patients that suffer from adverse events of chemotherapy, the onset of neuropathic pain is difficult to estimate. For this reason, biomarkers represent important diagnostic markers that may be used for therapeutic strategies and, in an ideal case, for the prediction of onset, intensity and duration of neuropathic pain even before the first symptoms arise in patients.
    Using animal models of neuropathic pain, we observe that oxidized lipids and epoxylipids are generated in nervous tissue and plasma even before neuropathic pain arises in the animals. We therefore suggest determination of the concentrations of these lipids by mass spectrometry (LC-MS/MS) in the plasma of patients as potential biomarkers for neuropathic pain. Using this method, high-risk patients may be identified early and pharmacological treatment may start before neuropathic pain is established. The early treatment may lead to a reduction or even prevention of neuropathic pain in these patients.

    摘要翻译： 神经性疼痛是一种治疗选择不当的虚弱疾病。 临床研究得出结论，早期治疗干预对于提高治疗成功率和改善神经性疼痛至关重要。 然而，在糖尿病患者或患有化疗不良事件的患者中，神经性疼痛的发作很难估计。 由于这个原因，生物标志物代表可用于治疗策略的重要诊断标志物，并且在理想情况下，甚至在患者出现第一症状之前预测神经性疼痛的发作，强度和持续时间。 使用神经性疼痛的动物模型，我们观察到即使在动物出现神经性疼痛之前，在神经组织和血浆中也会产生氧化脂质和环氧脂质。 因此，我们建议通过质谱法（LC-MS / MS）在患者血浆中测定这些脂质的浓度，作为神经性疼痛的潜在生物标志物。 使用这种方法，可以早期发现高危患者，并在神经性疼痛建立之前开始药物治疗。 早期治疗可能会导致这些患者的神经性疼痛减少甚至预防。